二元结果医疗决策支持系统临床试验的样本量计算。

IF 1.1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Sovremennye Tehnologii v Medicine Pub Date : 2022-01-01 DOI:10.17691/stm2022.14.3.01
O Yu Rebrova, A V Gusev
{"title":"二元结果医疗决策支持系统临床试验的样本量计算。","authors":"O Yu Rebrova,&nbsp;A V Gusev","doi":"10.17691/stm2022.14.3.01","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, software products for use in medicine are actively developed. Among them, the dominant share belongs to clinical decision support systems (CDSS), which can be intelligent (based on mathematical models obtained by machine learning methods or other artificial intelligence technologies) or non-intelligent. For the state registration of CDSSs as software medical products, clinical trials are required, and the protocol of trial is developed jointly by the developer and an authorized medical organization. One of the mandatory components of the protocol is the calculation of the sample size. This article discusses the calculation of the sample size for the most common case, the binary outcome in diagnostic/screening and predictive systems. For diagnostic/screening models, cases of a non-comparative study, comparative study with testing of the superiority hypothesis, comparative study with testing of a hypothesis of non-inferiority in cross-sectional studies are considered. For predictive models, cases of randomized controlled trials of the complex intervention \"prediction + prediction-dependent patient management\" with testing of the hypothesis of superiority and non-inferiority are considered. It is emphasized that representativeness of the sample and other design components are no less important in clinical trials than sample size. They are even more important since systematic biases in clinical trials are primary, and even the most sophisticated statistical analysis cannot compensate for design defects. The reduction of clinical trials to external validation of models (i.e. evaluation of accuracy metrics on external data) seems completely unreasonable. It is recommended to perform clinical trials with the design adequate to the tasks, so that further clinical and economic analysis and comprehensive assessment of medical technologies are possible. The sample size calculation methods described in the article can potentially be applied to a wider range of medical devices.</p>","PeriodicalId":51886,"journal":{"name":"Sovremennye Tehnologii v Medicine","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090914/pdf/","citationCount":"2","resultStr":"{\"title\":\"Sample Size Calculation for Clinical Trials of Medical Decision Support Systems with Binary Outcome.\",\"authors\":\"O Yu Rebrova,&nbsp;A V Gusev\",\"doi\":\"10.17691/stm2022.14.3.01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Currently, software products for use in medicine are actively developed. Among them, the dominant share belongs to clinical decision support systems (CDSS), which can be intelligent (based on mathematical models obtained by machine learning methods or other artificial intelligence technologies) or non-intelligent. For the state registration of CDSSs as software medical products, clinical trials are required, and the protocol of trial is developed jointly by the developer and an authorized medical organization. One of the mandatory components of the protocol is the calculation of the sample size. This article discusses the calculation of the sample size for the most common case, the binary outcome in diagnostic/screening and predictive systems. For diagnostic/screening models, cases of a non-comparative study, comparative study with testing of the superiority hypothesis, comparative study with testing of a hypothesis of non-inferiority in cross-sectional studies are considered. For predictive models, cases of randomized controlled trials of the complex intervention \\\"prediction + prediction-dependent patient management\\\" with testing of the hypothesis of superiority and non-inferiority are considered. It is emphasized that representativeness of the sample and other design components are no less important in clinical trials than sample size. They are even more important since systematic biases in clinical trials are primary, and even the most sophisticated statistical analysis cannot compensate for design defects. The reduction of clinical trials to external validation of models (i.e. evaluation of accuracy metrics on external data) seems completely unreasonable. It is recommended to perform clinical trials with the design adequate to the tasks, so that further clinical and economic analysis and comprehensive assessment of medical technologies are possible. The sample size calculation methods described in the article can potentially be applied to a wider range of medical devices.</p>\",\"PeriodicalId\":51886,\"journal\":{\"name\":\"Sovremennye Tehnologii v Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090914/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sovremennye Tehnologii v Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17691/stm2022.14.3.01\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sovremennye Tehnologii v Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17691/stm2022.14.3.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 2

摘要

目前,正在积极开发用于医学的软件产品。其中占主导地位的是临床决策支持系统(CDSS),它可以是智能的(基于机器学习方法或其他人工智能技术获得的数学模型),也可以是非智能的。cdss作为软件医疗产品在国家注册时,需要进行临床试验,试验方案由开发者与授权的医疗机构共同制定。该方案的强制性组成部分之一是计算样本量。本文讨论了最常见病例的样本量的计算,诊断/筛选和预测系统中的二元结果。对于诊断/筛选模型,在横断面研究中考虑非比较研究、优势假设检验的比较研究、非劣效假设检验的比较研究。对于预测模型,考虑了复杂干预“预测+依赖预测的患者管理”的随机对照试验案例,并检验了优势和非劣效假设。强调样本的代表性和其他设计成分在临床试验中的重要性不亚于样本量。由于临床试验中的系统偏差是主要的,即使是最复杂的统计分析也无法弥补设计缺陷,因此它们更加重要。将临床试验减少到模型的外部验证(即评估外部数据的准确性指标)似乎完全不合理。建议采用与任务相适应的设计进行临床试验,以便对医疗技术进行进一步的临床和经济分析和综合评估。本文中描述的样本量计算方法可以潜在地应用于更广泛的医疗设备。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Sample Size Calculation for Clinical Trials of Medical Decision Support Systems with Binary Outcome.

Currently, software products for use in medicine are actively developed. Among them, the dominant share belongs to clinical decision support systems (CDSS), which can be intelligent (based on mathematical models obtained by machine learning methods or other artificial intelligence technologies) or non-intelligent. For the state registration of CDSSs as software medical products, clinical trials are required, and the protocol of trial is developed jointly by the developer and an authorized medical organization. One of the mandatory components of the protocol is the calculation of the sample size. This article discusses the calculation of the sample size for the most common case, the binary outcome in diagnostic/screening and predictive systems. For diagnostic/screening models, cases of a non-comparative study, comparative study with testing of the superiority hypothesis, comparative study with testing of a hypothesis of non-inferiority in cross-sectional studies are considered. For predictive models, cases of randomized controlled trials of the complex intervention "prediction + prediction-dependent patient management" with testing of the hypothesis of superiority and non-inferiority are considered. It is emphasized that representativeness of the sample and other design components are no less important in clinical trials than sample size. They are even more important since systematic biases in clinical trials are primary, and even the most sophisticated statistical analysis cannot compensate for design defects. The reduction of clinical trials to external validation of models (i.e. evaluation of accuracy metrics on external data) seems completely unreasonable. It is recommended to perform clinical trials with the design adequate to the tasks, so that further clinical and economic analysis and comprehensive assessment of medical technologies are possible. The sample size calculation methods described in the article can potentially be applied to a wider range of medical devices.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Sovremennye Tehnologii v Medicine
Sovremennye Tehnologii v Medicine MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
1.80
自引率
0.00%
发文量
38
期刊最新文献
Sphingomyelins of Local Fat Depots and Blood Serum as Promising Biomarkers of Cardiovascular Diseases Neurogenetics of Brain Connectivity: Current Approaches to the Study (Review) Brain–Computer Interfaces with Intracortical Implants for Motor and Communication Functions Compensation: Review of Recent Developments Evaluation of the Feasibility of Using Commercial Wound Coatings as a Carrier Matrix for Bacteriophages Performance of the Models Predicting In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction with Predictors in Categorical and Continuous Forms
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1